Beta Lapachone Drug Asset Due Diligence Report 2026

This Beta Lapachone Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Beta Lapachone can convert its Small molecule drug profile and NQO1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Beta Lapachone (query alias: Beta Lapachone)
Modality / target	Small molecule drug; NQO1; NQO1 inhibitors
Highest global status	Phase 2
Originator	Arisyn
Active developers	Curome Biosciences Co., Ltd., Ajou University

The MCP disease footprint includes Cholangitis, Sclerosing, Neurodegenerative Diseases. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
No matched detailed trial record returned.

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Phase I trial of ARQ 501, an Activated Checkpoint Therapy (ACT) agent, in patients with advanced solid tumors

Phase 1; n=18; evaluation: Positive. Reported fields: PK(390 mg/m2 dose) = Up to the 390 mg/m2 dose, ARQ 501 exhibited apparent linear pharmacokinetics,

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Beta Lapachone addresses Cholangitis, Sclerosing, Neurodegenerative Diseases. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: NQO1 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2025-05-01	Cardinal Health entered into an agreement with GE Healthcare to manufacture and distribute Flyrcado	Approved	Financial terms not disclosed
2024-12-15	Pharming announces public cash offer to the shareholders of Abliva AB	Phase 2	US$66.1M stated total
2019-10-25	PTC Therapeutics completed the acquisition of substantially all of the assets of BioElectron Technology Corporation	Not disclosed	US$10.0M upfront; US$200.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Composition for improvement of sleep or for prevention or treatment of sleep disorders, containing beta-lapachone”. The milestone feed surfaced a patent-application signal described as “Composition for preventing or treating chronic myeloma leukemia comprising beta-lapachone”. The milestone feed surfaced a patent-application signal described as “Composition comprising beta-lapachone or pharmaceutically acceptable salt thereof as active ingredient for treating wound and promoting skin regeneration”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO